Notably, despite having elevated levels of FGF-23, in Stewart et al. [46], those patients were not hypophosphatemic, either because the FGF-23 secreted by plasma cells varied in some way from the FGF-23 secreted by other tumors or because of other effects myeloma has on phosphorus metabolism. The gene discussed is FGF23; the disease is plasma cell myeloma.